SlideShare a Scribd company logo
DATA INTEGRITY
In Pharmaceutical Industry
Overview
1. Guidelines
2. Principles of DI
3. Data Integrity Risk Assessment (DIRA)
4. Data Criticality and Risk
5. Design Robust Compliance System
6. Data interpretation and Good Documentation Practices (GDocP)
Principles of Data Integrity (DI)
1. Data recorded as per GMP requirement and ensuring data is complete, consistent and
accurate throughout the lifecycle i.e paper or electronic
2. Organisational culture, behaviour encouraging to create right environment to
implement effective Data integrity on site
3. Data governance policy should be effectively endorsed at the highest level
4. Data Integrity Risk Assessment (DIRA)
5. Develop system to maintain and control data, periodic DI audit
6. Contingency procedure should not impact on DI controls. Apply to automated
computerized system to paper-based system, vice versa.
7. Holistic approach for any identified DI weakness
8. Notification to regulatory authority where significant DI incident identify.
9. Effectively implementation of ALCOA+
Data Integrity Risk Assessment (DIRA)
1. Consider factors impacting on process or function on the system
2. Common factors are: Computerised system, People, SOP, training, Quality system
3. Automated validated system reduce DI risk
4. Human intervention influence on data record, report, retain, verification, poor
systematic control, poor validation plan increase DI risk
5. DI risk remediation action should be documented, discuss and review by Quality
management
6. DI risk remediation actions should categorise by long term and short term. Where
long term action require, short term action has clearly target problem
Data Criticality and Risk
1. Critical data influence on Quality, Safety and Efficacy decision
2. Risk of data deletion, amendment, exclusion without authorisation and lost of
traceability
3. Process complexity, inconsistency, inconclusive outcome increase data risk
4. Common data sources are Paper, electronic, Hybrid, other
4.1. Paper Data: Hand written, printed data require second independent verification (risk
reducing measure)
4.2. Electronic: Complexity of the electronic system. Validation of electronic system to
reduce risk e.g. functionality, configuration, user intervention, data lifecycle
4.3. Hybrid: Combination of paper and electronic data.
4.4. Other: photograph, image, photocopy where original copy fade control storage of
data.
Design Robust Compliance System
1. Synchronised clock system for traceable time stamp with correct time zone
2. Control over raw data recording and it’s accessibility
3. Use of controlled logbook with number page to prevent recreation of primary data
4. Access control of computerised system to prevent amendment of data, audit trail
5. Use of interface e.g. Barcode scanner, Automated weighing Printer, Badge access
system to eliminate manual entries and reduce human interaction
6. Trained people, validated system
7. Access of record , reconciliation of printouts to Data verification team
8. Promote work environment that provide sufficient time, equipment, clear
instruction
9. SME involvement in Risk assessment, Quality Metrics for DI
Design Robust Compliance System
1. Use of scriber to record data should be justifiable
 Contemporaneous recording
 Clearly identify who is performing task
 All involved persons should trained to carry out activity
 Task briefing should be given to all persons involved
 Document should be singed by all persons involved
Data Interpretation and GDocP
1. What information are consider as Data
 Original records
 True copies of original records
 Sourced data (Printout from HMI e.g. SIP, CIP, Autocalve, Balance, HPLC, FTIR)
 Metadata
 Reports printouts
 Any information recorded at the time of activity perform
 Data allows to reconstruct and evaluate carried out GxP activity.
Data Interpretation and GDocP
 GDocP are those measures that collectively and individually ensure Documentation,
whether paper or electronic are following the principles of ‘ALCOA+’
 Documents use for GMP purpose should comply with GDocP i.e. BMR, logbook,
Specification, SOP, Analytical method, Protocol, Qualification Doc, CofA, TA, PQR
 Document handling procedure i.e Retention, Archiving, Periodic review
ALCOA + (Plus)
Attributable Consistent
Legible Complete
Contemporaneous Enduring
Original Available
Accurate
Data Interpretation and GDocP
 ALCOA
Attributable – clear who has capture and
document the data
Legible – readable and stay in permanent
format throughout life cycle
Contemporaneous – recorded at the time
of activity
Original – first recorded data, not ‘True
copy’
Accurate – True representation of Fact
 ALCOA+
Consistent – recorded in same way
Complete – Complete pack of data
including metadata
Enduring – long lasting durable storage
(paper, electronic)
Available – Retrievable and accessible for
review
Data Interpretation and GDocP
2. What is Raw data?
 Original report, first captured information and should endure during lifecycle of data
 Raw data could be paper or electronic
 If data capture electronically and print as per requirement then electronic data is a
raw
raw data which can reproduce
 If electronic system does not store data then print out is the raw data
 If electronic system have limited storage capacity then data should be periodically
review and paper copy to keep
 Electronic data storage, back up and periodic review to carry out as per site
procedure
Data Interpretation and GDocP
3. What is Metadata?
 Describe the attribute of other data and provide context and meaning.
 It is a part of original data but original data has no meaning if context not provide
by metadata.
4. What is Data Governance?
 Any form of data generation are recorded, processed, retain and available to use
for
data lifecycle.
 Data ownership and accountability
 Data access restriction, handling, encourage reporting of errors, omissions, OOS
Data Interpretation and GDocP
5. What is Data lifecycle?
 Data to retain and accessible in original form from generation, recording, use,
retention, archive/retrieval and destruction to ensure DI.
6. Recording data
 Should meet ALCOA+ principles
 Recording methods should be controlled and traceable
7. Data transfer / migration
 Storage media can change without changing the original data
 Storage media, data transfer process should be validated, audit trail availability
 Electronic worksheet should be controlled
Data Interpretation and GDocP
8. Data Processing
 Original data should available throughout life cycle
 Data process should not manipulate data to get desirable result e.g. Chromatogram
9. Excluding Data
 Should demonstrate with valid scientific justification and recorded with original data
 Excluded data should retain with throughout lifecycle
10. Original Record
 First source of information cab ne paper, observation, electronic record including
any
supportive data require to re-generate the GxP activity.
 Original record can be static and dynamic
Data Interpretation and GDocP
11. True copy
 A verified copy by second person which contains same data, information as
original
copy. This can be paper, electronic and retain throughout the data lifecycle.
12. Computerised system transaction
 It can be single or series of operation to perform the transaction. This can be
perform manually or control by automated system
 Critical steps should perform, record contemporaneously and save before make
any change
 E-signature, audit trail should introduce to capture data even
Data Interpretation and GDocP
13. Audit trail
 A form of metadata containing information associated with actions that relate
to creation, modification or deletion of GxP records.
 Secure recording of any type modification of data such as creation, additions,
deletions, alterations e.g. Paper or Electronic
 Audit trail facilitate the reconstruction of historical event during investigation
 System should be risk assessed for clearly identified use access level
 Computerised system should always provide retention of audit trail to review
changes
 Where Audit trail not possible, alternative method should in in place e.g.
logbook
 Audit trail should review periodically, part of data approval by trained reviewer
Data Interpretation and GDocP
14. Electronic signature (e-sign)
 Digital form of signature equivalent in legal terms of hand written signature
 Control of e-sign: attributable, no manipulation, legible, security of access by
owner
 Where pdf, paper copy e-sign, metadata should be documented with original
 Method of authentication of e-sign should be risk assess
 Only inserted image , footnote without metadata is not adequate for e-sign
Data Interpretation and GDocP
15. Data review and approval
 Should be a SOP to describe review and approve data
 Error should be addressed as per procedure e.g. Comments, Deviation
 Correction, recording, process should follow ALCOA+
 Electronic report should customise to provide all necessary information require
for
review and approval of report and related documents
 If data provided by other organisation, then receiving organise should evaluate
the data
 Data integrity of data supplier and generator
 Clearly identify category of routine and periodic data review
Data Interpretation and GDocP
16. Computerised system user access/system administrator roles
 Access as per functionality appropriate to job role
 Company must able to demonstrate regarding user access level
 Individual login require for audit trail to ensure data integrity
 Generic user access should not be used, additional license purchase should be
available
 System not use for GxP purpose but contain GxP data must demonstrate control
over user access
 System admin rights should not conflict interest of data use
Data Interpretation and GDocP
17. Data retention
 Data archive , back up procedure and policy should available
 Data retention should ensure to protect data from deliberate, inadvertent
alteration or loss
 Data security should ensure by controlling measure or validate system
 Original/true copy paper data can be stored by validating scanning process
and control storage location
 Data destruction procedure should consider criticality and applicable legislative
retention requirements
Data Interpretation and GDocP
18. Archive and back up
 Designated secure area for long term, retention of data and metadata for the
purpose of verification of the process or activity
 Should be protected for any alteration and event like fire, flood, pest
 Should be an arrangement to permit recovery of data, able to perform full
verification
 Virtual system can be use for legacy system which are no longer supported
 If full data migration of original is not achievable, risk based approach in place to
protect data
 Original data pack including metadata configure to maintain for recovery including
disaster recovery
 Backup and recovery process should be validated, periodically tested, functionality
 Back up policy and procedure should be in place
 Back up policy should not affect retention policy
Data Interpretation and GDocP
19. File structure
 DI risk assessment should define GxP use, software functionality for intended use,
control and security over generated file
20. Validation for intended purpose
 Comply with regulatory requirement
 Functional verification should be demonstrated
 internal requalification schedule should be available
21. IT supplier and service provider
 For ‘cloud’ and ‘virtual’ service provider ownership, retrieval, retention, data security
should consider
 Impact of law application of geographical location where data are physically stored
 Technical agreement should clearly define responsibilities of contract giver and
acceptor
 Software/system restoration should be made as per GxP
Thank you

More Related Content

What's hot

ALCOA & ALCOA+
ALCOA & ALCOA+ALCOA & ALCOA+
ALCOA & ALCOA+
Guru Balaji .S
 
Data Integrity Training by Dr. A. Amsavel
Data Integrity Training   by Dr. A. AmsavelData Integrity Training   by Dr. A. Amsavel
Data Integrity Training by Dr. A. Amsavel
Dr. Amsavel A
 
Presentation on US FDA Data Integrity Guidance.
Presentation on US FDA  Data Integrity Guidance.Presentation on US FDA  Data Integrity Guidance.
Presentation on US FDA Data Integrity Guidance.
GMP EDUCATION : Not for Profit Organization
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
Vidyasagar P
 
GDP Training NS
GDP Training NSGDP Training NS
GDP Training NS
Neeraj Shrivastava
 
Data Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality IntegrationData Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality Integration
Obaid Ali / Roohi B. Obaid
 
Data integrity
Data integrityData integrity
Data integrity
Kiran Kota
 
GMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICESGMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICES
Omkar Phutane
 
21 cfr part 11 basic
21 cfr part 11 basic21 cfr part 11 basic
21 cfr part 11 basic
Bhagwatsonwane
 
Lab data integrity
Lab data integrity Lab data integrity
Lab data integrity
Rajesh Kapoor
 
Data integrity in pharmaceutical industry a brief overview
Data integrity in pharmaceutical industry a brief overviewData integrity in pharmaceutical industry a brief overview
Data integrity in pharmaceutical industry a brief overview
chaitanyasanjaykanad
 
Good Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdfGood Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdf
Md. Zakaria Faruki
 
Handling of Out of Specification Results
Handling of Out of Specification ResultsHandling of Out of Specification Results
Handling of Out of Specification Results
GMP EDUCATION : Not for Profit Organization
 
Data Integrity
Data IntegrityData Integrity
Data Integrity
Dr. Amsavel A
 
21 CFR part 11 Overview
21 CFR part 11 Overview21 CFR part 11 Overview
21 CFR part 11 Overview
Zahid Munir Choudhry
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
Piyush Tripathi
 
Good Documentation Practice (GDP)
Good Documentation Practice (GDP)Good Documentation Practice (GDP)
Good Documentation Practice (GDP)
AsthaNeupane
 
Gdp alcoa
Gdp  alcoaGdp  alcoa
Gdp alcoa
Shruti Kargutkar
 
21 CFR PART 11
21 CFR PART 1121 CFR PART 11
21 CFR PART 11
Dipak Patel
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
Shoab Malek (Certified Quality Auditor)
 

What's hot (20)

ALCOA & ALCOA+
ALCOA & ALCOA+ALCOA & ALCOA+
ALCOA & ALCOA+
 
Data Integrity Training by Dr. A. Amsavel
Data Integrity Training   by Dr. A. AmsavelData Integrity Training   by Dr. A. Amsavel
Data Integrity Training by Dr. A. Amsavel
 
Presentation on US FDA Data Integrity Guidance.
Presentation on US FDA  Data Integrity Guidance.Presentation on US FDA  Data Integrity Guidance.
Presentation on US FDA Data Integrity Guidance.
 
FDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixesFDA Data Integrity Issues - DMS hot fixes
FDA Data Integrity Issues - DMS hot fixes
 
GDP Training NS
GDP Training NSGDP Training NS
GDP Training NS
 
Data Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality IntegrationData Integrity & Culture of Quality Integration
Data Integrity & Culture of Quality Integration
 
Data integrity
Data integrityData integrity
Data integrity
 
GMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICESGMP - GOOD DOCUMENTATION PRACTICES
GMP - GOOD DOCUMENTATION PRACTICES
 
21 cfr part 11 basic
21 cfr part 11 basic21 cfr part 11 basic
21 cfr part 11 basic
 
Lab data integrity
Lab data integrity Lab data integrity
Lab data integrity
 
Data integrity in pharmaceutical industry a brief overview
Data integrity in pharmaceutical industry a brief overviewData integrity in pharmaceutical industry a brief overview
Data integrity in pharmaceutical industry a brief overview
 
Good Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdfGood Documentation Practice (GDocP).pdf
Good Documentation Practice (GDocP).pdf
 
Handling of Out of Specification Results
Handling of Out of Specification ResultsHandling of Out of Specification Results
Handling of Out of Specification Results
 
Data Integrity
Data IntegrityData Integrity
Data Integrity
 
21 CFR part 11 Overview
21 CFR part 11 Overview21 CFR part 11 Overview
21 CFR part 11 Overview
 
Data Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical CompaniesData Integrity Issues in Pharmaceutical Companies
Data Integrity Issues in Pharmaceutical Companies
 
Good Documentation Practice (GDP)
Good Documentation Practice (GDP)Good Documentation Practice (GDP)
Good Documentation Practice (GDP)
 
Gdp alcoa
Gdp  alcoaGdp  alcoa
Gdp alcoa
 
21 CFR PART 11
21 CFR PART 1121 CFR PART 11
21 CFR PART 11
 
Good documentation practice
Good documentation practiceGood documentation practice
Good documentation practice
 

Similar to Data integrity in Pharmaceutical industry

Phụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tínhPhụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tính
Công ty Cổ phần Tư vấn Thiết kế GMP EU
 
Data integrity nouri 10092020
Data integrity   nouri   10092020Data integrity   nouri   10092020
Data integrity nouri 10092020
Ahmed Nouri
 
Data Integrity AbbVie Presentation
Data Integrity AbbVie PresentationData Integrity AbbVie Presentation
Data Integrity AbbVie Presentation
Brian Sheerin
 
management information system module3
management information system module3management information system module3
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity
Bhaswat Chakraborty
 
Presentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspectivePresentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspective
TGA Australia
 
Lect 1b - Introduction to Pharmacy Informatics 1b.pdf
Lect 1b - Introduction to Pharmacy Informatics 1b.pdfLect 1b - Introduction to Pharmacy Informatics 1b.pdf
Lect 1b - Introduction to Pharmacy Informatics 1b.pdf
TSha7
 
TGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspectiveTGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspective
TGA Australia
 
computers in clinical development
 computers in clinical development computers in clinical development
computers in clinical development
SUJITHA MARY
 
Effects of IT on internal controls
Effects of IT on internal controlsEffects of IT on internal controls
Effects of IT on internal controls
Lou Foja
 
Research Data Management, Challenges and Tools - Per Öster
Research Data Management, Challenges and Tools - Per Öster Research Data Management, Challenges and Tools - Per Öster
Research Data Management, Challenges and Tools - Per Öster
LEARN Project
 
MPH07 Computers in clinical development.pptx
MPH07 Computers in clinical development.pptxMPH07 Computers in clinical development.pptx
MPH07 Computers in clinical development.pptx
BhuminJain1
 
05 Duplication and Preservation of Digital evidence - Notes
05 Duplication and Preservation of Digital evidence - Notes05 Duplication and Preservation of Digital evidence - Notes
05 Duplication and Preservation of Digital evidence - Notes
Kranthi
 
Documentation - The First and Last Exit in GMP
Documentation - The First and Last Exit in GMPDocumentation - The First and Last Exit in GMP
Documentation - The First and Last Exit in GMP
Obaid Ali / Roohi B. Obaid
 
Document Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automateDocument Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automate
Jeff Thomas
 
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
Target Health, Inc.
 
Quick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data IntegrityQuick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data Integrity
Peter Dellva
 
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters Corporation
 
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdfNovatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
patemalabanan
 
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREEA ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
ijcsa
 

Similar to Data integrity in Pharmaceutical industry (20)

Phụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tínhPhụ lục 11 GMPEU. Hệ thống máy tính
Phụ lục 11 GMPEU. Hệ thống máy tính
 
Data integrity nouri 10092020
Data integrity   nouri   10092020Data integrity   nouri   10092020
Data integrity nouri 10092020
 
Data Integrity AbbVie Presentation
Data Integrity AbbVie PresentationData Integrity AbbVie Presentation
Data Integrity AbbVie Presentation
 
management information system module3
management information system module3management information system module3
management information system module3
 
Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity Developing Protocols & Procedures for CT Data Integrity
Developing Protocols & Procedures for CT Data Integrity
 
Presentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspectivePresentation: Data Integrity – an international regulatory perspective
Presentation: Data Integrity – an international regulatory perspective
 
Lect 1b - Introduction to Pharmacy Informatics 1b.pdf
Lect 1b - Introduction to Pharmacy Informatics 1b.pdfLect 1b - Introduction to Pharmacy Informatics 1b.pdf
Lect 1b - Introduction to Pharmacy Informatics 1b.pdf
 
TGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspectiveTGA presentation: Data Integrity - an international regulatory perspective
TGA presentation: Data Integrity - an international regulatory perspective
 
computers in clinical development
 computers in clinical development computers in clinical development
computers in clinical development
 
Effects of IT on internal controls
Effects of IT on internal controlsEffects of IT on internal controls
Effects of IT on internal controls
 
Research Data Management, Challenges and Tools - Per Öster
Research Data Management, Challenges and Tools - Per Öster Research Data Management, Challenges and Tools - Per Öster
Research Data Management, Challenges and Tools - Per Öster
 
MPH07 Computers in clinical development.pptx
MPH07 Computers in clinical development.pptxMPH07 Computers in clinical development.pptx
MPH07 Computers in clinical development.pptx
 
05 Duplication and Preservation of Digital evidence - Notes
05 Duplication and Preservation of Digital evidence - Notes05 Duplication and Preservation of Digital evidence - Notes
05 Duplication and Preservation of Digital evidence - Notes
 
Documentation - The First and Last Exit in GMP
Documentation - The First and Last Exit in GMPDocumentation - The First and Last Exit in GMP
Documentation - The First and Last Exit in GMP
 
Document Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automateDocument Control in FDA Regulated Environments - When and how to automate
Document Control in FDA Regulated Environments - When and how to automate
 
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
A Pharma/CRO Partnership in the Design and Execution of Paperless Clinical Tr...
 
Quick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data IntegrityQuick Overview: Pharmaceutical Data Integrity
Quick Overview: Pharmaceutical Data Integrity
 
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
Waters: Reviewing Audit Trail Information in Empower Chromatography Data Soft...
 
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdfNovatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
Novatek- Regulatory Compliant User Requirement 21CFR Part 11 & Annex 11.pdf
 
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREEA ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
A ROBUST APPROACH FOR DATA CLEANING USED BY DECISION TREE
 

Recently uploaded

Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
NX Healthcare
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
shruti jagirdar
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
DrGirishJHoogar
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
rightmanforbloodline
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
Gokuldas Hospital
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
Université de Montréal
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
Josep Vidal-Alaball
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
MuskanShingari
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Gokuldas Hospital
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
FFragrant
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
phuakl
 
Case presentation On Urinary tract infection
Case presentation On Urinary tract infectionCase presentation On Urinary tract infection
Case presentation On Urinary tract infection
KarthyAks1
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
suvadeepdas911
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
NephroTube - Dr.Gawad
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
Gokuldas Hospital
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
KerlynIgnacio
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
LEFLOT Jean-Louis
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
Rahul Sen
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
Jyoti Bhaghasra
 
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIESLOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
ShraddhaTamshettiwar
 

Recently uploaded (20)

Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International TravelersTravel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
 
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
 
Recent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptxRecent advances on Cervical cancer .pptx
Recent advances on Cervical cancer .pptx
 
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfTest bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
 
How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.How to choose the best dermatologists in Indore.
How to choose the best dermatologists in Indore.
 
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
“Psychiatry and the Humanities”: An Innovative Course at the University of Mo...
 
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS)
 
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticalsacne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
 
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
 
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptxPost-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
 
Ageing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public HealthAgeing, the Elderly, Gerontology and Public Health
Ageing, the Elderly, Gerontology and Public Health
 
Case presentation On Urinary tract infection
Case presentation On Urinary tract infectionCase presentation On Urinary tract infection
Case presentation On Urinary tract infection
 
CBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdfCBL Seminar 2024_Preliminary Program.pdf
CBL Seminar 2024_Preliminary Program.pdf
 
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.GawadHemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
 
What are the different types of Dental implants.
What are the different types of Dental implants.What are the different types of Dental implants.
What are the different types of Dental implants.
 
pharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdfpharmacology for dummies free pdf download.pdf
pharmacology for dummies free pdf download.pdf
 
Cervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptxCervical Disc Arthroplasty ORSI 2024.pptx
Cervical Disc Arthroplasty ORSI 2024.pptx
 
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdfNAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
NAVIGATING THE HORIZONS OF TIME LAPSE EMBRYO MONITORING.pdf
 
Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1 Foundation of Yoga, YCB Level-3, Unit-1
Foundation of Yoga, YCB Level-3, Unit-1
 
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIESLOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
LOW BIRTH WEIGHT. PRETERM BABIES OR SMALL FOR DATES BABIES
 

Data integrity in Pharmaceutical industry

  • 2. Overview 1. Guidelines 2. Principles of DI 3. Data Integrity Risk Assessment (DIRA) 4. Data Criticality and Risk 5. Design Robust Compliance System 6. Data interpretation and Good Documentation Practices (GDocP)
  • 3. Principles of Data Integrity (DI) 1. Data recorded as per GMP requirement and ensuring data is complete, consistent and accurate throughout the lifecycle i.e paper or electronic 2. Organisational culture, behaviour encouraging to create right environment to implement effective Data integrity on site 3. Data governance policy should be effectively endorsed at the highest level 4. Data Integrity Risk Assessment (DIRA) 5. Develop system to maintain and control data, periodic DI audit 6. Contingency procedure should not impact on DI controls. Apply to automated computerized system to paper-based system, vice versa. 7. Holistic approach for any identified DI weakness 8. Notification to regulatory authority where significant DI incident identify. 9. Effectively implementation of ALCOA+
  • 4. Data Integrity Risk Assessment (DIRA) 1. Consider factors impacting on process or function on the system 2. Common factors are: Computerised system, People, SOP, training, Quality system 3. Automated validated system reduce DI risk 4. Human intervention influence on data record, report, retain, verification, poor systematic control, poor validation plan increase DI risk 5. DI risk remediation action should be documented, discuss and review by Quality management 6. DI risk remediation actions should categorise by long term and short term. Where long term action require, short term action has clearly target problem
  • 5. Data Criticality and Risk 1. Critical data influence on Quality, Safety and Efficacy decision 2. Risk of data deletion, amendment, exclusion without authorisation and lost of traceability 3. Process complexity, inconsistency, inconclusive outcome increase data risk 4. Common data sources are Paper, electronic, Hybrid, other 4.1. Paper Data: Hand written, printed data require second independent verification (risk reducing measure) 4.2. Electronic: Complexity of the electronic system. Validation of electronic system to reduce risk e.g. functionality, configuration, user intervention, data lifecycle 4.3. Hybrid: Combination of paper and electronic data. 4.4. Other: photograph, image, photocopy where original copy fade control storage of data.
  • 6. Design Robust Compliance System 1. Synchronised clock system for traceable time stamp with correct time zone 2. Control over raw data recording and it’s accessibility 3. Use of controlled logbook with number page to prevent recreation of primary data 4. Access control of computerised system to prevent amendment of data, audit trail 5. Use of interface e.g. Barcode scanner, Automated weighing Printer, Badge access system to eliminate manual entries and reduce human interaction 6. Trained people, validated system 7. Access of record , reconciliation of printouts to Data verification team 8. Promote work environment that provide sufficient time, equipment, clear instruction 9. SME involvement in Risk assessment, Quality Metrics for DI
  • 7. Design Robust Compliance System 1. Use of scriber to record data should be justifiable  Contemporaneous recording  Clearly identify who is performing task  All involved persons should trained to carry out activity  Task briefing should be given to all persons involved  Document should be singed by all persons involved
  • 8. Data Interpretation and GDocP 1. What information are consider as Data  Original records  True copies of original records  Sourced data (Printout from HMI e.g. SIP, CIP, Autocalve, Balance, HPLC, FTIR)  Metadata  Reports printouts  Any information recorded at the time of activity perform  Data allows to reconstruct and evaluate carried out GxP activity.
  • 9. Data Interpretation and GDocP  GDocP are those measures that collectively and individually ensure Documentation, whether paper or electronic are following the principles of ‘ALCOA+’  Documents use for GMP purpose should comply with GDocP i.e. BMR, logbook, Specification, SOP, Analytical method, Protocol, Qualification Doc, CofA, TA, PQR  Document handling procedure i.e Retention, Archiving, Periodic review ALCOA + (Plus) Attributable Consistent Legible Complete Contemporaneous Enduring Original Available Accurate
  • 10. Data Interpretation and GDocP  ALCOA Attributable – clear who has capture and document the data Legible – readable and stay in permanent format throughout life cycle Contemporaneous – recorded at the time of activity Original – first recorded data, not ‘True copy’ Accurate – True representation of Fact  ALCOA+ Consistent – recorded in same way Complete – Complete pack of data including metadata Enduring – long lasting durable storage (paper, electronic) Available – Retrievable and accessible for review
  • 11. Data Interpretation and GDocP 2. What is Raw data?  Original report, first captured information and should endure during lifecycle of data  Raw data could be paper or electronic  If data capture electronically and print as per requirement then electronic data is a raw raw data which can reproduce  If electronic system does not store data then print out is the raw data  If electronic system have limited storage capacity then data should be periodically review and paper copy to keep  Electronic data storage, back up and periodic review to carry out as per site procedure
  • 12. Data Interpretation and GDocP 3. What is Metadata?  Describe the attribute of other data and provide context and meaning.  It is a part of original data but original data has no meaning if context not provide by metadata. 4. What is Data Governance?  Any form of data generation are recorded, processed, retain and available to use for data lifecycle.  Data ownership and accountability  Data access restriction, handling, encourage reporting of errors, omissions, OOS
  • 13. Data Interpretation and GDocP 5. What is Data lifecycle?  Data to retain and accessible in original form from generation, recording, use, retention, archive/retrieval and destruction to ensure DI. 6. Recording data  Should meet ALCOA+ principles  Recording methods should be controlled and traceable 7. Data transfer / migration  Storage media can change without changing the original data  Storage media, data transfer process should be validated, audit trail availability  Electronic worksheet should be controlled
  • 14. Data Interpretation and GDocP 8. Data Processing  Original data should available throughout life cycle  Data process should not manipulate data to get desirable result e.g. Chromatogram 9. Excluding Data  Should demonstrate with valid scientific justification and recorded with original data  Excluded data should retain with throughout lifecycle 10. Original Record  First source of information cab ne paper, observation, electronic record including any supportive data require to re-generate the GxP activity.  Original record can be static and dynamic
  • 15. Data Interpretation and GDocP 11. True copy  A verified copy by second person which contains same data, information as original copy. This can be paper, electronic and retain throughout the data lifecycle. 12. Computerised system transaction  It can be single or series of operation to perform the transaction. This can be perform manually or control by automated system  Critical steps should perform, record contemporaneously and save before make any change  E-signature, audit trail should introduce to capture data even
  • 16. Data Interpretation and GDocP 13. Audit trail  A form of metadata containing information associated with actions that relate to creation, modification or deletion of GxP records.  Secure recording of any type modification of data such as creation, additions, deletions, alterations e.g. Paper or Electronic  Audit trail facilitate the reconstruction of historical event during investigation  System should be risk assessed for clearly identified use access level  Computerised system should always provide retention of audit trail to review changes  Where Audit trail not possible, alternative method should in in place e.g. logbook  Audit trail should review periodically, part of data approval by trained reviewer
  • 17. Data Interpretation and GDocP 14. Electronic signature (e-sign)  Digital form of signature equivalent in legal terms of hand written signature  Control of e-sign: attributable, no manipulation, legible, security of access by owner  Where pdf, paper copy e-sign, metadata should be documented with original  Method of authentication of e-sign should be risk assess  Only inserted image , footnote without metadata is not adequate for e-sign
  • 18. Data Interpretation and GDocP 15. Data review and approval  Should be a SOP to describe review and approve data  Error should be addressed as per procedure e.g. Comments, Deviation  Correction, recording, process should follow ALCOA+  Electronic report should customise to provide all necessary information require for review and approval of report and related documents  If data provided by other organisation, then receiving organise should evaluate the data  Data integrity of data supplier and generator  Clearly identify category of routine and periodic data review
  • 19. Data Interpretation and GDocP 16. Computerised system user access/system administrator roles  Access as per functionality appropriate to job role  Company must able to demonstrate regarding user access level  Individual login require for audit trail to ensure data integrity  Generic user access should not be used, additional license purchase should be available  System not use for GxP purpose but contain GxP data must demonstrate control over user access  System admin rights should not conflict interest of data use
  • 20. Data Interpretation and GDocP 17. Data retention  Data archive , back up procedure and policy should available  Data retention should ensure to protect data from deliberate, inadvertent alteration or loss  Data security should ensure by controlling measure or validate system  Original/true copy paper data can be stored by validating scanning process and control storage location  Data destruction procedure should consider criticality and applicable legislative retention requirements
  • 21. Data Interpretation and GDocP 18. Archive and back up  Designated secure area for long term, retention of data and metadata for the purpose of verification of the process or activity  Should be protected for any alteration and event like fire, flood, pest  Should be an arrangement to permit recovery of data, able to perform full verification  Virtual system can be use for legacy system which are no longer supported  If full data migration of original is not achievable, risk based approach in place to protect data  Original data pack including metadata configure to maintain for recovery including disaster recovery  Backup and recovery process should be validated, periodically tested, functionality  Back up policy and procedure should be in place  Back up policy should not affect retention policy
  • 22. Data Interpretation and GDocP 19. File structure  DI risk assessment should define GxP use, software functionality for intended use, control and security over generated file 20. Validation for intended purpose  Comply with regulatory requirement  Functional verification should be demonstrated  internal requalification schedule should be available 21. IT supplier and service provider  For ‘cloud’ and ‘virtual’ service provider ownership, retrieval, retention, data security should consider  Impact of law application of geographical location where data are physically stored  Technical agreement should clearly define responsibilities of contract giver and acceptor  Software/system restoration should be made as per GxP

Editor's Notes

  1. NOTE: To change the image on this slide, select the picture and delete it. Then click the Pictures icon in the placeholder to insert your own image.